Discovery Park has named the successful applicants that will take part in its first ever Reactor programme, designed to supercharge life sciences firms’ potential to scale.
Ten companies will each benefit from eight weeks of high-level mentoring and coaching worth £15,000.This support will first analyse their businesses and then importantly position them for growth. The coaching will follow the Triple Chasm Company’s data-based approach to commercialising innovation.
Those on the programme include companies developing or delivering clinical diagnostics, drug and medical device discovery, and providing services to biotech and clinical organisations. The companies selected are: VisusNano, Scitegrity, Psyros Diagnostics, Curtis Analytics, Vitarka Therapeutics, Testavec, Genestack, MedConcept, SpOtOn Clinical Diagnostics and BioMavericks.
Mentors will include Isabel Fox, general partner, Outsized Ventures; Jo Pisani, strategic advisor, non-executive director and trustee and Dr Claire Thompson, CEO, Agility Life Sciences.
From left to right; Dr Joanna Gould, Dr Martino Picardo and Dr Vineeta Tripathi.
In addition, each of the companies will have access to some of Triple Chasm’s analysis tools for a year and membership of Discovery Park’s community, including business services. The Triple Chasm Company’s approach combines the understanding of the three ‘chasms’, or stages where business development stalls, with analysis of a company’s technology and commercialisation readiness level and twelve vectors which drive growth. It is supported by data from thousands of high-growth companies across the world.
Discovery Park, which is based in Kent, is a leading life sciences and innovation hub and it is home to more than 160 science-based companies, including Pfizer. The site offers high quality laboratory, office and manufacturing facilities, the space and support to expand, access to local finance, and a strong local scientific talent pool. It was named recently as one of six prestigious UK Life Sciences Opportunity Zones by the UK Government. Its new Reactor Programme will be an on-going initiative to accelerate the growth of small and medium-sized science companies.
Dr Martino Picardo, Chair of Discovery Park, said: “The UK is home to innovative companies leading the field of life sciences, globally. Accelerating their growth allows the sector, and the wider community, to benefit faster from ground breaking, innovative healthcare solutions. We’re confident that we’ve selected companies with growth potential to be part of the first Reactor programme and we look forward to helping them turn their development plans into positive action.
“The Reactor programme, along with the launch of our new incubator facility in 2022, will go some way to transforming Discovery Park into a world-class hub for the translation of life sciences research, where innovation and collaboration are driving forward the next generation of healthcare initiatives and discoveries.”
Based at Discovery Park, VisusNano aims to revolutionise cataract surgery in humans and animals with their intraocular lens implant and has been selected for the programme. Dr Joanna Gould, Chief Executive Officer, VisusNano said:
“We are very excited about being selected and understanding what the Discovery Park network has to offer. We have benefitted from other accelerator programmes previously which focused on the start up stage. The Reactor Programme seems much more about scaling for growth.”
Also selected for the programme is Vitarka Therapeutics, a biotech company determined to help combat late-stage cancers. Dr Vineeta Tripathi, Chief Executive Officer, Vitarka Therapeutics said:
“Vitarka Therapeutics is thrilled to be selected for the Discovery Park Reactor programme. We eagerly look forward to developing and growing our venture with invaluable mentorship from a wide array of experts, driven by the Triple Chasm data-based approach. The networking will enable us to build long lasting relationships on our journey to bring novel first line therapeutics to patients dying from cancer without treatment options.”
The hashtag for the programme is #DPReactor.
For more information please contact:
M: 07766 742 142
ABOUT DISCOVERY PARK (www.discovery-park.co.uk)
Discovery Park is a thriving part of the South East’s life science community. The site offers high quality laboratory, office and manufacturing facilities, the space and support to expand, access to local finance, and a strong local scientific talent pool. It was named recently one of six prestigious UK Life Sciences Opportunity Zones by the UK Government, and is developing its vision for a Manufacturing Village.
The growing tenant community includes Pfizer, which built the site’s reputation as a centre for drug discovery and discovered some of the most famous drugs in the world here. Other tenants include Algaecytes, Canterbury Christ Church University, Concept Life Sciences, eXroid, Genea Biomedx, LGC, Viatris, Psyros Diagnostics, Salvensis, VisusNano and Wren Healthcare. Discovery Park is home to 160+ companies employing 3,500 employees in total. With easy connections to London, Europe and the world Discovery Park is a great place to build and grow your biotech, medtech or pharma business. Discover more via our website: www.discovery-park.co.uk email: firstname.lastname@example.org or call: 01304 614060. You can also follow us on social media.
ABOUT THE TRIPLE CHASM COMPANY
The Triple Chasm Company was established to exploit the insights from a five-year global research programme which looked at how innovative companies grow and scale. The results generated a seminal book published in 2017 called ‘Camels, Tigers and Unicorns: Re-thinking science and technology-enabled innovation’. This was followed by ‘The Scale-up Manual’ which converted these insights into practical tools for growth companies.
The Triple Chasm Company provides a digital platform, tools and associated services to intervention agencies, investors, and strategic consulting partners who work with growth companies, focused on the following building blocks
Maturity of any proposition, based on cumulative customer growth, the three Chasms where growth is interrupted and the concept of Commercialisation Readiness Level (CRL), which is distinct from Technology Readiness Level (TRL)
Meso-economic Vectors (growth drivers), which enable relative priorities to be quantified along the commercialisation journey
Understanding new and emerging market-space-centric value chains
Commercialisation Intensity of any proposition along its commercialisation journey
Ideological stance, which defines overall priorities, best exemplified in the concept of Sustainability Stance, which provides the first effective antidote to green-washing.
To find out more visit HOME | Triple Chasm Model (thetriplechasm.com)
Companies selected for the Discovery Park Reactor programme
- Scitegrity Scitegrity | Chemical Regulations Compliance
- VisusNano VisusNano | A drug-eluting intraocular lens revolutionising cataract surgery
- Testavec Home | Testavec
- Genestack Multi-omics data management and integration experts (genestack.com)
- Vitarka Vitarka Therapeutics Ltd
- Medconcept MedConcept
- Psyros Home | Psyros
- Curtis Analytics Acrylamide In Food Testing Services – Curtis Analytics Ltd
- SpOtOn Diagnostics SpOtOn Clinical Diagnostics (spotoncd.com)